Medtronic plc’s Stock Price Drops to $81.38, Experiences 5.11% Dip: A Deep Dive into MDT’s Market Performance

Medtronic plc (MDT)

81.38 USD -4.38 (-5.11%) Volume: 10.71M

Medtronic plc’s stock price stands at 81.38 USD, experiencing a drop of -5.11% this trading session with a trading volume of 10.71M, marking a year-to-date percentage change of -1.21%, signifying a volatile market performance for MDT.

Latest developments on Medtronic plc

Medtronic Plc‘s stock experienced fluctuations today after reporting full year and fourth quarter fiscal 2024 financial results, beating profit estimates but disappointing with a weaker-than-expected outlook. The medical device giant saw strong sales from neurology devices, leading to a dividend increase. Despite beating quarterly profit estimates and surpassing revenue expectations, Medtronic’s margins were down. The company also initiated new clinical studies to expand indications for its Hugo device. Jump Financial LLC increased its stock holdings in Medtronic, while the MiniMed 780G AID System received accolades. Despite these positive developments, Medtronic’s stock underperformed compared to competitors, raising questions about its current momentum and share price.

Medtronic plc on Smartkarma

Analysts at Baptista Research on Smartkarma have provided bullish coverage on Medtronic Plc, highlighting the company’s strong performance in the fiscal ’24 third quarter. The research reports emphasize Medtronic’s mid-single-digit revenue growth, driven by key business segments like Core Spine, Cardiac Surgery, and Structural Heart. The analysts also point out the significant role of innovation-driven technologies such as robotics and AI in driving future growth for the company.

In another report by Baptista Research on Smartkarma, analysts discuss Medtronic Plc‘s potential to revolutionize hypertension treatment with new FDA approvals. The company’s recent performance, with mid-single-digit revenue growth across various business segments like Cardiovascular and Medical Surgical, has been positively highlighted. The analysts also note the strong growth in Diabetes and synergistic businesses like Aortic and Cardiac Surgery, indicating a promising outlook for Medtronic’s future growth prospects.

A look at Medtronic plc Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Medtronic Plc, a company that develops medical products, has received positive scores across the board on the Smartkarma Smart Scores. With high scores in Value, Dividend, Growth, and Momentum, the company is positioned well for long-term success. While its Resilience score is slightly lower, Medtronic Plc‘s overall outlook remains strong.

Medtronic Plc‘s diverse range of products for various medical conditions, including heart management, pain relief, and movement disorders, have helped solidify its position in the market. With a strong focus on innovation and a global presence, the company is well-equipped to continue its growth and provide value to investors through dividends and potential for further expansion.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma